Abstract

A COMPARISION OF HEALTH CARE UTILIZATION AND COST OF CHILDREN ANDADOLESCENTSWITH BIPOLAR DISORDERTREATEDWITH ATYPICAL ANTIPSYCHOTIC MONOTHERAPYVERSUS MOOD STABILIZER MONOTHERAPY Jing Y, Guo JJ, Patel NC, Heaton PC, Li H, Kelton CM University of Cincinnati, Cincinnati, OH, USA, University of Georgia, Augusta, GA, USA, Bristol-Myers Squibb Company, Singapore, Singapore OBJECTIVE: To compare health care utilization and cost of children and adolescents with bipolar disorder treated with atypical antipsychotic (ATYP) versus with mood stabilizer (MS) monotherapy. METHODS: We conducted a retrospective cohort study using Pharmetrics administrative claims data from January 1, 1998 to December 31, 2002. The study population included youths (6 < AGE < 19). RESULTS: After matching on the propensity score, 486 subject pairs were retained. On average, ATYP monotherapy subjects had fewer bipolar-related office visits (p = 0.0041), but similar bipolar-related outpatient hospitalization (p = 0.084), bipolar-related days of hospitalization (p = 0.1707), and bipolar-related emergency department visits (p = 1.00). ATYP monotherapy subjects had a lower cost of bipolar-related office visits (p = 0.0246) but higher medication costs (p < 0.0001). There were no cost differences between groups for bipolar-related emergency department visits (p = 0.5477), bipolar-related outpatient hospitalization (p = 0.9817), and bipolar-related inpatient hospitalizations (p = 0.521). Total bipolar-related medical service (p = 0.6501) and general health-related medical service (p = 0.885) costs were also not significantly different between the two groups. CONCLUSION: Compared to patients with MS monotherapy, patients with ATYP monotherapy had fewer bipolar-related office visits and higher medication costs, but similar total bipolarrelated and overall medical service costs.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.